Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease.
Yoshimura Y, Yamanouchi M, Koizumi R, Mizuno H, Oba Y, Kurihara S, Suwabe T, Tsunoda S, Kishioka A, Takeuchi T, Tanimizu H, Kamido H, Yoshimoto M, Sugimoto H, Ikuma D, Tanaka K, Inoue N, Sekine A, Hasegawa E, Wada T, Ubara Y, Sawa N.
Yoshimura Y, et al. Among authors: yoshimoto m.
Rheumatology (Oxford). 2025 Jan 25:keaf050. doi: 10.1093/rheumatology/keaf050. Online ahead of print.
Rheumatology (Oxford). 2025.
PMID: 39862405